Patents by Inventor Miles William Carroll
Miles William Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130236479Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: April 19, 2013Publication date: September 12, 2013Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles William Carroll, Abigail Lamikanra, Alan John Kingsman
-
Publication number: 20120213822Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: ApplicationFiled: February 21, 2012Publication date: August 23, 2012Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Patent number: 8133681Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: GrantFiled: March 20, 2008Date of Patent: March 13, 2012Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Patent number: 8084249Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: February 26, 2010Date of Patent: December 27, 2011Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20110065173Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: February 26, 2010Publication date: March 17, 2011Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20110052577Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: July 28, 2010Publication date: March 3, 2011Applicant: Oxford Biomedica (UK) LimitedInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7888115Abstract: There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.Type: GrantFiled: July 10, 2009Date of Patent: February 15, 2011Assignee: Oxford Biomedica (UK) LimitedInventors: Miles William Carroll, Susan Mary Kingsman, Irina Redchenko
-
Publication number: 20100233126Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: ApplicationFiled: December 14, 2009Publication date: September 16, 2010Inventors: MILES WILLIAM CARROLL, KEVIN ALAN MYERS
-
Publication number: 20100158884Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.Type: ApplicationFiled: February 3, 2010Publication date: June 24, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Miles William Carroll, Susan Mary Kingsman
-
Publication number: 20100040539Abstract: The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications.Type: ApplicationFiled: May 15, 2008Publication date: February 18, 2010Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Alan Kingsman, Susan Mary Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Kevin Alan Myers
-
Patent number: 7659383Abstract: Canine and feline 5T4 polypeptide sequences and nucleotide sequences encoding them are provided. A vector system comprising a nucleic acid encoding 5T4 and a 5T4-specific agent are also provided.Type: GrantFiled: July 8, 2008Date of Patent: February 9, 2010Assignee: Oxford Biomedica (UK) LimitedInventors: Kevin Alan Myers, Noel Drury, Miles William Carroll
-
Patent number: 7635687Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: December 30, 2002Date of Patent: December 22, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Patent number: 7531648Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: March 22, 2002Date of Patent: May 12, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20090047307Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.Type: ApplicationFiled: March 20, 2008Publication date: February 19, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
-
Publication number: 20090017532Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: ApplicationFiled: August 6, 2008Publication date: January 15, 2009Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Patent number: 7148035Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: GrantFiled: March 24, 2000Date of Patent: December 12, 2006Assignee: Oxford Biomedica (UK) LimitedInventors: Miles William Carroll, Kevin Alan Myers
-
Patent number: 6852703Abstract: A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.Type: GrantFiled: June 4, 1998Date of Patent: February 8, 2005Assignee: Oxford Biomedica (UK) LimitedInventors: Susan Mary Kingsman, Christopher Robert Bebbington, Fiona Margaret Ellard, Miles William Carroll, Kevin Alan Myers
-
Publication number: 20040265275Abstract: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.Type: ApplicationFiled: February 6, 2004Publication date: December 30, 2004Applicant: Oxford BioMedica (UK) LimitedInventors: Miles William Carroll, Kevin Alan Myers
-
Publication number: 20040131591Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: ApplicationFiled: December 30, 2002Publication date: July 8, 2004Inventors: Alan John Kingsman, Christopher Robert Bebbington, Miles William Carroll, Fiona Margaret Ellard, Susan Mary Kingsman, Kevin Alan Myers, Abigail Lamikanra
-
Publication number: 20030147907Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.Type: ApplicationFiled: May 29, 2001Publication date: August 7, 2003Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim